Shell Asset Management CO I Mab Transaction History

Shell Asset Management CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$8.27 - $18.43 $17,367 - $38,703	-2,100 Closed	0 $0
Q1 2022 May 04, 2022	SELL	$12.54 - $46.93 $130,415 - $488,072	-10,400 Reduced 83.2%	2,100 $34,000
Q4 2021 Feb 09, 2022	BUY	$45.28 - $74.5 $566,000 - $931,250	12,500 New	12,500 $592,000
Q3 2021 Nov 04, 2021	SELL	$57.18 - $84.43 $17,154 - $25,329	-300 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$47.86 - $83.95 $14,358 - $25,185	300 New	300 $25,000

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.